Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis
Conditions
Interventions
Namilumab
Locations
12
United States
Kinevant Study Site
Palo Alto, California, United States
Kinevant Study Site
Denver, Colorado, United States
Kinevant Study Site
New Haven, Connecticut, United States
Kinevant Study Site
Gainesville, Florida, United States
Kinevant Study Site
Iowa City, Iowa, United States
Kinevant Study Site
Baltimore, Maryland, United States
Start Date
August 23, 2022
Primary Completion Date
November 15, 2022
Completion Date
December 13, 2022
Last Updated
April 17, 2025
Lead Sponsor
Kinevant Sciences GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions